Fludarabine/Cyclophosphamide Conditioning Regimen in Aplastic Anemia Patients Receiving Matched-Sibling Donor Transplant Is Non-inferior to ATG/Cyclophosphamide: A Single-Center Experience from Pakistan
Table 2
Distribution of Flu/Cy verses ATG/Cy with transplant characteristics ().
Flu/cy
ATG/cy
value
Median
Median
(IQR)
(IQR)
Age (years)
17 (12-24)
12 (8-18)
0.001
Time duration from diagnosis till transplant (months)
3 (2-4)
3 (2-4)
0.267
Time duration from transplant till follow-up (months)
30 (8-49)
24 (3-64)
0.813
(%)
(%)
Gender mismatch
Female to male
13 (14.8)
6 (14.3)
0.941
Same
75 (85.2)
36 (85.7)
Cyclosporine use
Yes
79 (89.8)
35 (85.3)
0.392
No
9 (10.2)
7 (16.7)
Graft source
PB
58 (65.9)
23 (54.8)
0.351
BM
22 (25.0)
12 (28.6)
PB/BM
8 (9.1)
7 (16.6)
Primary graft failure
Yes
5 (5.7)
8 (19.0)
0.027
No
83 (94.3)
34 (81.0)
Secondary graft failure
Yes
9 (10.2)
7 (16.7)
0.392
No
79 (89.8)
35 (83.3)
GvHD
Yes
16 (18.2)
2 (4.8)
0.038
No
72 (81.8)
40 (95.2)
Acute GvHD
Yes
7 (8.0)
1 (2.4)
0.436
No
81 (92.0)
41 (97.6)
Chronic GvHD
Yes
8 (9.1)
2 (4.8)
0.499
No
80 (90.9)
40 (95.2)
Relapse
Yes
8 (9.1)
1 (2.4)
0.270
No
80 (90.9)
41 (97.6)
value calculated by using Mann–Whitney test, chi-square test, and Fisher’s exact test.
